2023 World Conference on Lung Cancer (Posters)-P2.08. A Phase 2 Study of Mecbotamab Vedotin (BA3011), a CAB-AXL-ADC, Alone or in Combination with Nivolumab

P2.08. A Phase 2 Study of Mecbotamab Vedotin (BA3011), a CAB-AXL-ADC, Alone or in Combination with Nivolumab - PDF(Slides)

Back to course

Pdf Summary

The document is a summary of a Phase 2 study of Mecbotamab Vedotin (BA3011), an antibody-drug conjugate (ADC), alone or in combination with Nivolumab for the treatment of patients with advanced solid tumors. Mecbotamab Vedotin is a conditionally active biologic (CAB) anti-AXL antibody-drug conjugate designed to reduce off-tumor toxicity and improve pharmacokinetics. AXL, a cell-surface receptor protein tyrosine kinase, is highly expressed in various solid tumor types and has been associated with resistance to chemotherapy and other therapies. The study aims to evaluate the efficacy and safety of BA3011 alone or in combination with nivolumab in patients with metastatic non-small cell lung cancer (NSCLC) who have failed PD-1/L1, EGFR, or ALK inhibitors. The study design involves administering BA3011 intravenously to adult patients in different dosing regimens. The primary endpoints of the study include overall response rate (ORR) and incidence of adverse events (AEs). Secondary endpoints include duration of response (DOR), progression-free survival (PFS), best overall response (BOR), and overall survival (OS). The study will also explore plasma concentrations of ADC, total antibody, and MMAE, immunogenicity, relationship between tumor AXL status and clinical response, and potential biomarkers for patient selection or correlation with antitumor activity. The study is ongoing, and the results are yet to be reported.

Asset Subtitle

Edwin Yau

Meta Tag

Speaker Edwin Yau

Topic Metastatic NSCLC: Immunotherapy - TIPs

Keywords

Mecbotamab Vedotin

BA3011

antibody-drug conjugate

Nivolumab

solid tumors

AXL

non-small cell lung cancer

overall response rate

adverse events

biomarkers